This strategic report from Espicom puts the spotlight on current and future drugs that will be used in the treatment of Type I and Type II diabetes, providing industry and investors with a comprehensive overview of the market in the medium term.
Additional Information
REPORT CONTENTS SUMMARY
An analysis of diabetes prevalence and trends worldwide, plus current treatment options
An assessment of 7 insulin/insulin analogues currently available and continuing research to identify alternative methods of administration
Featuring
Unique 5-point assessment and scoring for each product examining key areas such as product novelty, clinical data and competition
Sales forecasts by year to 2013 for key launched and pipeline products
The withdrawal of Pfizer’s Exubera and safety concerns over the thiazolidinediones has not reduced interest in this fast growing global sector. New products, drug delivery technologies and therapeutic approaches continue apace.
It is estimated that around 250 million people are living with diabetes today and this number will increase to around 380 million by 2025.
Diabetes has become a major cause of premature illness and death in most countries, mainly through the increased risk of cardiovascular disease. In 2005, an estimated 1.1 million people around the world died directly from diabetes. The number of people whose death was recorded as heart disease or kidney failure where diabetes was a contributory factor is, however, considerably higher. Each year, diabetes related causes account for 3.8 million deaths; equivalent to one death every ten seconds and claiming the lives of as many people as HIV/AIDS.
The economic impact...
The prevention and treatment of diabetes and its complications cost around US$232 billion in 2007. By 2025, the cost is likely to exceed US$302.5 billion. In the US, the total economic cost of diabetes was estimated to be US$174 billion in 2007, of which US$116 billion was medical expenditure; US$27 billion was for diabetes care, US$58 billion was for chronic complications related to diabetes, and US$31 billion was attributed to general medical costs. In the UK, around 10% of the NHS budget is spent on treating diabetes and its complications. This equates to around £9 billion (US$16.2 billion). In Japan, general medical expenditure on diabetes amounted to ¥1,116.5 billion (US$10.7 billion) in 2005.
Understand the prospects for this US$26.3 billion sector
We estimate the global diabetes therapy market at around US$26.3 billion in 2009. By 2013, the market is expected to grow to around US$34.5 billion
Oral diabetes drugs account for around 39% of the total market value. Metformin is the recommended first-line therapy for Type II diabetes and accounts for around 11-12% of the total market by value. Other oral agents include sulphonylureas, thiazolidinediones (TZDs or glitazones), glinides and alpha-glucosidase inhibitors. Many of these are widely available generically; sales of leading proprietary oral agents amounted to US$7 billion in 2007.
Hope still for novel drug delivery
Despite the commercial failure of Pfizer’s inhaled insulin, Exubera, alternative methods of delivering insulin to patients remain of interest to developers. Of particular interest are Mannkind’s Afresa, an inhaled insulin product that has recently completed Phase III trials, and Generex Oral-lyn from Generex Biotechnology, a buccal spray formulation in Phase III in the US, which has recently been approved for marketing in Ecuador, India and Lebanon.
New approaches introduced: GLP-1 agonists and DPP-4 inhibitors
Two new classes of drugs have recently entered the market, both of which work on the incretin system: injectable glucagon-like peptide-1 (GLP-1) agonists and oral dipeptidyl peptidase-4 (DPP-4) inhibitors. GLP-1 agonists, also known as incretin mimetics, stimulate insulin secretions from beta cells in the pancreas in response to food intake, in a glucose dependent manner. DPP-4 inhibitors inhibit the DPP-4 enzyme, which results in an increase in circulation of the incretin hormone, GLP-1.
Key questions answered include:
Which markets will see the most significant growth in diabetes incidence?
What drug delivery approaches are showing promise and who is developing them?
What commercial impact are safety issues having on GSK’s Avandia?
How did sanofi-aventis boost sales of Lantus in 2008?
To what degree will Novartis’ Galvus be able to compete with Merck’s Januvia in the DPP-4 inhibitor battle?
The rapidly increasing patient pool and high unmet clinical need will translate into a continuing increase in revenue for several years to come
(0 items)
